**Abstract**

**Objective:** Previous research has suggested a link between typical antipsychotic use and the development of cataracts, but the association between atypical antipsychotics and cataracts remains unclear in schizophrenia (SZ).

**Methods:** A retrospective nested case-control study was conducted using data from the National Health Insurance Database of Taiwan between the year of 2000 and 2011. A total of 2,144 SZ patients with cataracts and 2,222 controls matched for age, sex, and index date were included. Antipsychotic exposure was categorized by type, duration, and daily dose, and the association between antipsychotic exposure and cataract development was assessed using a conditional logistic regression analysis.

**Results:** We found that the severity of physical comorbidities, concurrent antidepressant use, and comorbidity with glaucoma or other retinal disorders were associated with an increased risk for cataract development. Alternatively, we did not find significant associations between continuous use of clozapine, risperidone, paliperidone, ziprasidone, olanzapine, quetiapine, amisulpride, zotepine or aripiprazole and risk of cataract development in SZ patients.

**Conclusions:** We did not detect any association between atypical antipsychotic use and risk of cataract development in SZ patients. However, given that SZ patients often have risk factors for developing cataract such as diabetes mellitus, hypertension, and metabolic syndrome, mental health care providers should ensure that patients receive regular ocular evaluations. Future studies with longitudinal ocular evaluations in patients using atypical antipsychotics are warranted to conﬁrm our ﬁndings.
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